OGT releases first in a new line of cancer microarrays
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the first in a number of new microarrays for use in cancer research. The new CytoSure™ Haematological Cancer +SNP array is optimised for the study of the haematological malignancies Chronic Lymphocytic Leukaemia (CLL) and Multiple Myeloma (MM), as well as Myeloproliferative Neoplasms (MPN) and Myelodysplastic Syndromes (MDS). The new array offers confident detection of both copy number variation (CNV) and loss of heterozygosity (LOH) on a single chip for these diseases. This is achieved by utilising OGT’s novel array design, which combines long oligo array comparative genomic hybridisation (aCGH) probes for CNV detection with fully validated single nucleotide polymorphism (SNP) content for identifying LOH.
The probes on the new array have been optimised to target regions known to be important in haematological cancers, while providing good backbone coverage. These features facilitate the rapid, reliable identification of key genomic aberrations, while the complimentary, industry-leading CytoSure Interpret Software allows intuitive, single-click data analysis. Using the new array, researchers can move quickly and assuredly from processing their samples to generating relevant biological insight.
James Clough, Vice President OGT Clinical & Genomic Solutions, commented: “OGT has worked in collaboration with leading researchers to develop the CytoSure Haematological Cancer +SNP array. The new array is the first member of a rapidly expanding portfolio we are developing for the genetic analysis of cancerous lesions, with several other additions set to be released in the near future.”
The new CytoSure™ Haematological Cancer +SNP array offers reliable and accurate aCGH and LOH detection on a single array by utilising a unique SNP probe design. Analysis is carried out using an intensity-based comparison between the two SNP alleles, meaning that no changes to the standard aCGH protocol are required and any reference sample can be used. This allows the two tests to operate effectively on the same array. In addition, CytoSure arrays utilise 60-mer oligonucleotide probes, which have been shown to offer higher signal-to-noise ratios and increased specificity and sensitivity, providing the highest data quality possible. For optimum performance, the array can be combined with the CytoSure Genomic DNA Labelling Kit, which offers high signal intensities enabling easier allele discrimination.
OGT will be exhibiting, discussing and presenting the new arrays at several meetings around the world over the coming months. These include the International Society of Cellular Oncology (ISCO) Congress 2012 in Mallorca, Spain (4-8 March), the 31st UK Cancer Cytogenetics Group Meeting in Birmingham, UK (22-23 March) and the Australian Society of Cytogenetics (ASOC) Meeting 2012 in Port Stephens, Australia (23-25 March). Visit the events page of the OGT website for more information.
Further information about the new CytoSure Haematological Cancer +SNP array can be found at www.ogt.co.uk/cancer
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: email@example.com ; W: www.ogt.co.uk ; Twitter: @OxfordGeneTech
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.